The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 **FORM D**

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number: 3235-0076
Expires: August 31, 2015
Estimated average burden
hours per
response: 4.00

1. Issuer's Identity					
CIK (Filer ID Number)	Previous Names	X None	Entity Type		
0001454789			X Corporation		
Name of Issuer			Limited Partnership		
CATABASIS PHARMACEUTIC	ALS INC		Limited Liability Company		
Jurisdiction of Incorporation/O					
DE			General Partnership		
Year of Incorporation/Organiza	ation		Business Trust		
Over Five Years Ago			Other (Specify)		
X Within Last Five Years (Sp	pecify Year) 2008				
Yet to Be Formed					
2. Principal Place of Busines	s and Contact Information				
Name of Issuer					
CATABASIS PHARMACEUTIC	ALS INC	Ot t			
Street Address 1 19 BLACKSTONE STREET		Street Address 2			
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer		
CAMBRIDGE	MA	02139	617-349-1970		
3. Related Persons					
Last Name	First Name		Middle Name		
Milne	Jill		Middle Name		
Street Address 1	Street Address 2				
19 Blackstone Street	Circuit / Idan coo E				
City	State/Province/Co	ountry	ZIP/PostalCode		
Cambridge	MA	·	02139		
Relationship: X Executive Of	ficer X Director Promoter				
Clarification of Response (if Ne	ecessary):				
Last Name	First Name		Middle Name		
Jirousek	Michael				
Street Address 1	Street Address 2				
19 Blackstone Streeet					
City	State/Province/Co	ountry	ZIP/PostalCode		
Cambridge	MA		02139		
Relationship: X Executive Of	ficer X Director Promoter				
Clarification of Response (if Ne	ecessary):				
Last Name	First Name		Middle Name		
Thomajan	Chris				
Street Address 1	Street Address 2				
19 Blackstone Street					

City	State/Province/Country	ZIP/PostalCode		
Cambridge Relationship: X Executive Officer Direct	MA ctor Promoter	02139		
Relationship. X Executive Officer Direct	ctor Promoter			
Clarification of Response (if Necessary):				
4. Industry Group				
4. madady Group				
Agriculture	Health Care	Retailing		
Banking & Financial Services	Biotechnology	Restaurants		
Commercial Banking	Health Insurance	Technology		
Insurance	Hospitals & Physicians	Computers		
Investing	X Pharmaceuticals	Telecommunications		
Investment Banking Pooled Investment Fund	Other Health Care			
	Manufacturing	Other Technology		
Is the issuer registered as an investment company under	Real Estate	Travel Airlines & Airports		
the Investment Company Act of 1940?	Commercial			
Yes No	Construction	Lodging & Conventions		
Other Banking & Financial Services		Tourism & Travel Services		
Business Services	REITS & Finance	Other Travel		
Energy	Residential	Other		
Coal Mining	Other Real Estate			
Electric Utilities				
Energy Conservation				
Environmental Services				
Oil & Gas				
Other Energy				
5. Issuer Size				
Revenue Range OR	Aggregate Net Asset Va	alue Range		
No Revenues	No Aggregate Net As	sset Value		
\$1 - \$1,000,000	\$1 - \$5,000,000			
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000			
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,00			
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,0	000,000		
Over \$100,000,000	Over \$100,000,000			
X Decline to Disclose	Decline to Disclose			
Not Applicable	Not Applicable			
6. Federal Exemption(s) and Exclusion(s	c) Claimed (select all that apply)			
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505			
Rule 504 (b)(1)(i)	X Rule 506			
Rule 504 (b)(1)(ii)	Securities Act Secti	ion 4(5)		
Rule 504 (b)(1)(iii)				

Section	n 3(c)(1)	Section 3(c)(9)	
Section	n 3(c)(2)	Section 3(c)(10)	
Section	n 3(c)(3)	Section 3(c)(11)	
Section	n 3(c)(4)	Section 3(c)(12)	
	1 3(c)(5)	Section 3(c)(13)	
	1 3(c)(6)	Section 3(c)(14)	
Section	1 3(c)(7)		
7. Type of Filing			
New Notice Date of First Sale 2008-12-31 First Sale Yet X Amendment	to Occur		
8. Duration of Offering			
Does the Issuer intend this offering to last more than one year?	Yes X	No	
9. Type(s) of Securities Offered (select all that apply)			
Equity		Pooled Investment Fund Interests	
X Debt		Tenant-in-Common Securities	
Option, Warrant or Other Right to Acquire Another Security		Mineral Property Securities	
Security to be Acquired Upon Exercise of Option, Warrant or Right to Acquire Security	Other	Other (describe)	
10. Business Combination Transaction			
Is this offering being made in connection with a business combin merger, acquisition or exchange offer?	ation trans	saction, such as a Yes X No	
Clarification of Response (if Necessary):			
11. Minimum Investment			
Minimum investment accepted from any outside investor \$0 USE)		
12. Sales Compensation			
Recipient	Recipie	nt CRD Number X None	
(Associated) Broker or Dealer X None		ated) Broker or Dealer CRD Number X None	
Street Address 1		ddress 2	
City		rovince/Country	ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Fore	ign/non-US	
13. Offering and Sales Amounts			
Total Offering Amount \$2,000,000 USD or Indefinite			
Total Amount Sold \$1,075,000 USD			
Total Remaining to be Sold \$925,000 USD or Indefinite			
Clarification of Response (if Necessary):			
14. Investors			
Select if securities in the offering have been or may be sold enter the number of such non-accredited investors who alrea			
Regardless of whether securities in the offering have been or investors, enter the total number of investors who already ha	r may be s	old to persons who do not qualify as accredited	6

15. Sales Commissions & Finder's Fees Expenses
Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions \$0 USD Estimate
Finders' Fees \$0 USD Estimate
Clarification of Response (if Necessary):
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
\$0 USD Estimate
Clarification of Response (if Necessary):
Signature and Submission

Terms of Submission

file this notice.

In submitting this notice, each issuer named above is:

 Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to

- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
CATABASIS PHARMACEUTICALS INC	/s/ Chris Thomajan	Chris Thomajan	Chief Financial Officer	2009-05-12

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.